ABBVIE
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 480
- Registration Number
- NCT05814627
- Locations
- 🇯🇵
Hokkaido Medical Center For Rheumatic Diseases /ID# 270019, Sapporo-shi, Hokkaido, Japan
🇺🇸AZ Arthritis and Rheumotology Research, PLLC - Flagstaff /ID# 253431, Flagstaff, Arizona, United States
🇺🇸Arizona Arthritis and Rheumatology Research - Glendale Office /ID# 255018, Glendale, Arizona, United States
An Observational Study to Assess Change in Disease Activity and Adverse Events of Rinvoq in Adult Participants With Moderate to Severe Ulcerative Colitis (UC) in Japan
- Conditions
- First Posted Date
- 2023-03-30
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 300
- Registration Number
- NCT05791526
- Locations
- 🇯🇵
Kinshukai Infusion Clinic /ID# 253199, Osaka-shi, Osaka, Japan
🇯🇵National Hospital Organization Osaka National Hospital /ID# 257042, Osaka-shi, Osaka, Japan
🇯🇵Osaka Metropolitan University Hospital /ID# 258319, Osaka-shi, Osaka, Japan
Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.
- First Posted Date
- 2023-03-24
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 110
- Registration Number
- NCT05782907
- Locations
- 🇺🇸
Children's Specialty Group /ID# 256966, Norfolk, Virginia, United States
🇭🇺Semmelweis Egyetem /ID# 251083, Budapest, Hungary
🇺🇸NYU Langone Hospital - Long Island /ID# 250136, Mineola, New York, United States
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2023-03-16
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 240
- Registration Number
- NCT05771428
- Locations
- 🇯🇵
Nara Medical University Hospital /ID# 252564, Kashihara-shi, Nara, Japan
🇬🇧St Pancras Clinical Research /ID# 249006, London, United Kingdom
🇬🇧NeuroClin Limited(Previously Glasgow Memory Clinic) /ID# 249787, Motherwell, United Kingdom
A Study to Assess Adverse Events and Change in Disease Activity in Pediatric Participants (Age 6 Months to <2 Years) With Functional Constipation Who Are Treated With Linaclotide
- First Posted Date
- 2023-03-08
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 30
- Registration Number
- NCT05760313
- Locations
- 🇧🇬
UMHAT Sveti Georgi /ID# 250808, Plovdiv, Bulgaria
🇧🇬UMHAT Kanev /ID# 248931, Ruse, Bulgaria
🇺🇸Velocity Clinical Research Phoenix /ID# 263871, Phoenix, Arizona, United States
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
- First Posted Date
- 2023-03-03
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 128
- Registration Number
- NCT05753501
- Locations
- 🇺🇸
Arizona Oncology Associates, PC-HOPE /ID# 252351, Tempe, Arizona, United States
🇪🇸Hospital Universitario Vall d'Hebron /ID# 260447, Barcelona, Spain
🇺🇸Stanford Cancer Center - Palo Alto /ID# 249683, Palo Alto, California, United States
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
- Conditions
- Interventions
- First Posted Date
- 2023-02-28
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 545
- Registration Number
- NCT05748483
- Locations
- 🇨🇿
Praglandia /ID# 247511, Prague, Praha 5, Czechia
🇩🇪Universitaetsklinikum Carl Gustav Carus Dresden /ID# 246040, Dresden, Sachsen, Germany
🇧🇪Universitair Ziekenhuis Brussel /ID# 246959, Jette, Bruxelles-Capitale, Belgium
A Study to Assess Adverse Events and Effectiveness of Injected JUVÉDERM® VOLITE™ Gel Filler for Change in Neck Lines in Adult Chinese Participants
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 159
- Registration Number
- NCT05741034
- Locations
- 🇨🇳
China-Japan Friendship Hospital /ID# 243984, Beijing, Beijing, China
🇨🇳Huashan Hospital, Fudan University /ID# 244044, Shanghai, Shanghai, China
🇨🇳Beijing Hospital /ID# 243982, Beijing, Beijing, China
Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2023-02-22
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 104
- Registration Number
- NCT05738850
- Locations
- 🇺🇸
Anaheim Clinical Trials LLC /ID# 254178, Anaheim, California, United States
🇺🇸Acpru /Id# 249639, Grayslake, Illinois, United States
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
- Conditions
- Interventions
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 450
- Registration Number
- NCT05711394
- Locations
- 🇺🇸
Rehabilitation & Neurological Services /ID# 248517, Huntsville, Alabama, United States
🇺🇸Preferred Research Partners /ID# 249729, Little Rock, Arkansas, United States
🇺🇸Advanced Research Center /ID# 251381, Anaheim, California, United States